A new study by Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) found that 92 per cent of Colombian patients using the company’s cannabis oil formulations reported some degree of improvement in chronic pain.
On Tuesday, the multinational cannabis operator announced the results of a clinical study published in the journal Frontiers in Pain Research where it showed that 70 per cent of patients reported a 50 per cent improvement in chronic pain after four weeks of treatment with the cannabis oils.
The study describes the short, mid and long-term efficacy of two THC and CBD oil formulations including one with a balanced 1:1 ratio and one with a 1:25 ratio.
It also found that seven out of ten patients did not suffer from adverse effects and those who did report side effects said they were mild, transient and faded after 12 weeks.
First author and Global Scientific Director at Khiron Guillermo Moreno-Sanz said the company believes the results are generalizable across patient populations, given the results are “extremely well-aligned” with those reported by other researchers studying similar clinical populations just like the long-standing medical cannabis access programs in Israel and Canada.
Read more: Khiron partners with largest Mexican non-profit for children with disabilities
Read more: 80% of patients report reduced symptoms after using cannabis oil: Khiron study
For the study, medical researchers from Khiron Life Sciences and doctors from Khiron’s Zerenia Clinics evaluated 2112 patients diagnosed with chronic pain that were receiving treatment using Khiron’s oil-based cannabis formulations.
Patients received the treatment at the Latin American Institute of Neurology and Nervous System (ILANS)-Zerenia clinic in Bogota, Colombia between May and September of 2021 and responded to questionnaires monitoring the degree of clinical improvement as well as side effects.
Most of the participants were women with an average of 58 years of age while one-third of the patients were over 65 years old.
“The global impact and economic burden of chronic pain in our society, mounting medical evidence will increase access to cannabinoid-based medicines worldwide,” Khiron CEO Alvaro Torres said.
“The recent vote in the United States House of Representatives promoting medical research on cannabis clearly shows the pressing need to develop effective and safe cannabis-based medication for suffering patients worldwide,” he added.
Khiron operates Zerenia Clinics in Colombia, Peru, Germany, the United Kingdom and Brazil. It also recently partnered with the largest non-profit focusing on children with disabilities in Mexico and is set to commence medical cannabis sales soon.
Follow Natalia Buendia Calvillo on Twitter